Another vote for cancer immunotherapy came in the form of $50 million in class A stock-sale money for Conkwest Inc., including $48 million from Nantworks Inc. founder and well-known biotech entrepreneur Patrick Soon-Shiong plus $2 million from Sorrento Therapeutics Inc.